Deep vein thrombosis landmark trials in treatment

Deep Vein Thrombosis Microchapters
Home
Patient Information
Overview
Classification
Pathophysiology
Causes
Differentiating Deep vein thrombosis from other Diseases
Epidemiology and Demographics
Risk Factors
Triggers
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Approach
Assessment of Clinical Probability and Risk Scores
Assessment of Probability of Subsequent VTE and Risk Scores
History and Symptoms
Physical Examination
Laboratory Findings
Ultrasound
Venography
CT
MRI
Other Imaging Findings
Treatment
Treatment Approach
Medical Therapy
IVC Filter
Invasive Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Special Scenario
Upper extremity DVT
Recurrence
Pregnancy
Trials
Landmark Trials
Case Studies
Case #1
Deep vein thrombosis landmark trials in treatment On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Deep vein thrombosis landmark trials in treatment
CDC on Deep vein thrombosis landmark trials in treatment
Deep vein thrombosis landmark trials in treatment in the news
Blogs on Deep vein thrombosis landmark trials in treatment
Directions to Hospitals Treating Deep vein thrombosis
Risk calculators and risk factors for Deep vein thrombosis landmark trials in treatment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Ujjwal Rastogi, MBBS [2]

Landmark Clinical Trials

Trial comparing Low-molecular-weight Heparin With Unfractionated Heparin

A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. (1991)

• Patient enrollment: 166 patients
• Purpose: To compare subcutaneous low molecular weight heparin with intravenous unfractionated heparin in the treatment of deep vein thrombosis .
• Result: Both "therapeutic efficacy" and "intention to-treat" analyses showed that subcutaneous CY 216 in fixed doses based only on body weight was more effective on the Arnesen and Marder phlebographic scores than continuous i.v. standard heparin with daily dose adjustment according to results of coagulation tests. There was no increase in the risks of pulmonary embolism, haemorrhage or clot extension.